Purpose: Hyperthermic intraperitoneal chemotherapy is continuously under evaluation in ovarian cancer. The purpose of the present study was to evaluate the effect of chemotherapy, drug concentration and temperature. Materials and Methods: A human ovarian carcinoma cell line was used. The effect of hyperthermia combined with chemotherapy was analyzed. Results: When hyperthermia was combined with chemotherapy, the 50% lethal dose (LD50) decreased with the duration of exposure. The effect of temperature was similar between 39 and 43°C for a 30-min exposure. For a 60- to 90-min exposure, the LD50 was equivalent between 38 and 43°C. Beyond 40°C, an increase in platinum salt concentration was necessary to obtain similar results according to the duration of exposure. Conclusions: The cytotoxic effect of the combination seemed to be potentiated and limited at 40°C.

Keywords:
Hyperthermia, Chemotherapy, Platinum salt, Ovarian cancer cells
1.
Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, Thun MJ: Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96.
2.
Ozols RF: Update on the management of ovarian cancer. Cancer J 2002;2(suppl 1): S22–S30.
3.
Cannistra SA: Cancer of the ovary. N Engl J Med 2004;351:2519–2529.
4.
Gadducci A, Sartori E, Maggino T, Zola P, Landoni F, Fanucchi A, Palai N, Alessi C, Ferrero AM, Cosio S, Cristofani R: Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study. Gynecol Oncol 1998;68:150–155.
5.
Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, Wheeler S, Swart AM, Qian W, Torri V, Floriani I, Jayson G, Lamont A, Tropé C, ICON and AGO Collaborators: Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. Lancet 2003;361:2099–2106.
6.
Alberts DS: Treatment of refractory and recurrent ovarian cancer. Semin Oncol 1999;26(suppl 1):8–14.
7.
Rutledge F, Burns BC: Chemotherapy for advanced ovarian cancer. Am J Obstet Gynecol 1966;96:761–772.
8.
Alberts DS, Liu PY, Hannigan EV, O’Toole R, Williams SD, Young JA, Franklin EW, Clarke-Pearson DL, Malviya VK, Du Beshter B: Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. N Engl J Med 1996;335:1950–1955.
9.
Markman M, Bundy BN, Alberts DS, Fowler JM, Clark-Pearson DL, Carson LF, Wadler S, Sickel J: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001;19:1001–1007.
10.
Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, Copeland LJ, Walker JL, Burger RA, Gynecologic Oncology Group: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006;354:34–43.
11.
Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Boot H, Zoetmulder FA: Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003;21:3737–3743.
12.
Los G, Mutsaers PH, van der Vijgh WJ, Baldew GS, de Graaf PW, McVie JG: Direct diffusion of cis-diamminedichloroplatinum (II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380–3384.
13.
Kusamura S, Dominique E, Baratti D, Younan R, Deraco M: Drugs, carrier solutions and temperature in hyperthermic intraperitoneal chemotherapy. J Surg Oncol 2008;98:247–252.
14.
Smeenk RM, Verwaal VJ, Zoetmulder FA: Toxicity and mortality of cytoreduction and intraoperative hyperthermic intraperitoneal chemotherapy in pseudomyxoma peritonei – a report of 103 procedures. Eur J Surg Oncol 2006;32:186–190.
15.
Shido A, Ohmura S, Yamamoto K, Kobayashi T, Fujimura T, Yonemura Y: Does hyperthermia induce peritoneal damage in continuous hyperthermic peritoneal perfusion? World J Surg 2000;24:507–511.
16.
Zeamari S, Floot B, Van der Vange N, Stewart FA: Pharmacokinetics and pharmacodynamics of cisplatin after intraoperative hyperthermic intraperitoneal chemoperfusion (HIPEC). Anticancer Res 2003;23:1643–1648.
17.
Moran BJ, Mukherjee A, Sexton R: Operability and early outcome in 100 consecutive laparotomies for peritoneal malignancy. Br J Surg 2006;93:100–104.
18.
Glehen O, Cotte E, Lifante JC, Arvieux C, Moles N, Brigand C, Beaujard AC, François Y, Gilly FN: Peritoneal carcinomatosis in digestive cancers: cytoreductive surgery combined with intraperitoneal chemohyperthermia. The experience in Centre Hospitalier et Universitaire Lyon Sud (CHLS). Acta Chir Belg 2006;106:285–290.
19.
Elias D, Raynard B, Boige V, Laplanche A, Estphan G, Malka D, Pocard M: Impact of the extent and duration of cytoreductive surgery on postoperative haematological toxicity after intraperitoneal chemohyperthermia for peritoneal carcinomatosis. J Surg Oncol 2005;90:220–225.
20.
Sapareto SA, Hopwood LE, Dewey WC, Raju MR, Gray JW: Effects of hyperthermia on survival and progression of Chinese hamster ovary cells. Cancer Res 1978;38:393–400.
21.
Imai S, Maeda H, Kiyozuka Y, Noda T, Moriyama I, Ichijo M: Characterization of the CA125 antigen secreted from a newly established human ovarian cancer cell line (SHIN 3). Acta Pathol Jpn 1989;39:43–49.
22.
Wallner KE, De Gregorio MW, Li GC: Hyperthermic potentiation of cis-diamminenedichloroplatinum (II) cytotoxicity in Chinese hamster ovary cells resistant to the drug. Cancer Res 1986;46:6242–6245.
23.
Dickson JA, Ellis HA: Stimulation of tumour cell dissemination by raised temperature (42 degrees C) in rats with transplanted Yoshida tumours. Nature 1974;248:354–358.
24.
Giovanella BC, Stehlin JS Jr, Morgan AC: Selective lethal effect of supranormal temperatures on human neoplastic cells. Cancer Res 1976;36:3944–3950.
25.
Gerweck LE: Hyperthermia in cancer therapy: the biological basis and unresolved questions. Cancer Res 1985;45:3408–3414.
26.
Oleson JR, Calderwood SK, Coughlin CT, Dewhirst MW, Gerweck LE, Gibbs FA Jr, Kapp DS: Biological and clinical aspects of hyperthermia in cancer therapy. Am J Clin Oncol 1988;11:368–380.
27.
Reinhold HS, Endrich B: Tumour microcirculation as a target for hyperthermia. Int J Hyperthermia 1986;2:111–137.
28.
Lefor AT, Foster CE 3rd, Sartor W, Engbrecht B, Fabian DF, Silverman D: Hyperthermia increases intercellular adhesion molecule-1 expression and lymphocyte adhesion to endothelial cells. Surgery 1994;116:214–220.
29.
Dewey WC: Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 1994;10:457–483.
30.
Streffer C: Aspects of metabolic change after hyperthermia. Recent Results Cancer Res 1988;107:7–16.
31.
Mohamed F, Marchettini P, Stuart OA, Urano M, Sugarbaker PH: Thermal enhancement of new chemotherapeutic agents at moderate hyperthermia. Ann Surg Oncol 2003;10:463–468.
32.
Glehen O, Stuart OA, Mohamed F, Sugarbaker PH: Hyperthermia modifies pharmacokinetics and tissue distribution of intraperitoneal melphalan in a rat model. Cancer Chemother Pharmacol 2004;54:79–84.
33.
Glehen O, Kwiatkowski F, Sugarbaker PH, Elias D, Levine EA, De Simone M, Barone R, Yonemura Y, Cavaliere F, Quenet F, Gutman M, Tentes AA, Lorimier G, Bernard JL, Bereder JM, Porcheron J, Gomez-Portilla A, Shen P, Deraco M, Rat P: Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of the peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. J Clin Oncol 2004;22:3284–3292.
34.
Elias D, Detroz B, Debaene B, Damia E, Leclercq B, Rougier P, Lasser P: Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia: reliable and unreliable concepts. Hepatogastroenterology 1994;41:207–213.
35.
Elias D, Ouellet JF: Intraperitoneal chemohyperthermia: rationale, technique, indications, and results. Surg Oncol Clin North Am 2001;10:915–933.
36.
Cohen JD, Robins HI: Hyperthermic enhancement of cis-diamine-1,1-cyclobutane dicarboxylate platinum (II) cytotoxicity in human leukaemia cells in vitro. Cancer Res 1987;47:4335–4337.
37.
Ohno S, Siddik ZH, Kido Y, Zwelling LA, Bull JM: Thermal enhancement of drug uptake and DNA adducts as a possible mechanism for the effect of sequencing hyperthermia on cisplatin-induced cytotoxicity in L1210 cells. Cancer Chemother Pharmacol 1994;34:302–306.
38.
Kusumoto T, Holden SA, Ara G, Teicher BA: Hyperthermia and platinum complexes: time between treatments and synergy in vitro and in vivo. Int J Hyperthermia 1995;11:575–586.
39.
Ohtsubo T, Saito H, Tanaka N, Tsuzuki H, Saito T, Kano E: In vitro effect of hyperthermia on chemoenhancement and uptake of cisplatin in human pharyngeal carcinoma KB cells. Chemotherapy 1997;1:43–50.
40.
Ohtsubo T, Saito H, Matsumoto H, Hayashi S, Shioura H, Kitai R, Saito T, Kano E: In vitro effects of hyperthermia combined with cisplatin or peplomycin on the human maxillary carcinoma cell line IMC-2. Int J Hyperthermia 1997;13:59–67.
41.
Beketic-Oreskovic L, Jaski M, Oreskovic S, Osmark M: Hyperthermia modulation of resistance to cis-diamminedichloroplatinum (II) in human larynx carcinoma cells. Int J Hyperthermia 1997;13:205–214.
42.
Hettinga JV, Lemstra W, Meijer C, Dam WA, Uges DR, Konings AW, De Vries EG, Kampinga HH: Mechanism of hyperthermic potentiation of cisplatin action in cisplatin-sensitive and -resistant tumour cells. Br J Cancer 1997;75:1735–1743.
43.
Berenbaum MC: What is synergy? Pharmacol Rev 1989;41:93–141.
44.
Bourhis J, Mornex F: Biological principles of chemotherapy. Cancer Radiother 1998;2:657–662.
45.
Glehen O, Mohamed F, Gilly FN: Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219–228.
46.
Mann BD, Storm FK, Morton DL, Bertelsen CA, Korn EL, Kaiser LR, Kern LR: Predictability of response to clinical thermochemotherapy by the clonogenic assay. Cancer 1983;52:1389–1394.
47.
Atallah D, Marsaud V, Radanyi C, Kornprobst M, Rouzier R, Elias D, Renoir JM: Thermal enhancement of oxaliplatin-induced inhibition of cell proliferation and cell cycle progression in human carcinoma cell lines. Int J Hyperthermia 2004;20:405–419.
48.
Van der Heijden AG, Verhaegh G, Jansen CF, Schalken JA, Witjes JA: Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol 2005;173:1375–1380.
49.
Istomin YP, Zhavrid EA, Alexandrova EN, Sergeyeva OP, Petrovich SV: Dose enhancement effect of anticancer drugs associated with increased temperature in vitro. Exp Oncol 2008;30:56–59.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.